Immunomodulatory Effects of Pevonedistat, a NEDD8-Activating Enzyme (NAE) Inhibitor, in Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Best, Scott R. [1 ]
Kittai, Adam [2 ]
Rowland, Taylor [1 ]
Bruss, Nur [1 ]
Spurgeon, Stephen E. [2 ]
Berger, Allison [3 ]
Moran, Amy [1 ]
Danilov, Alexey V. [2 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[3] Takeda Pharmaceut Int Co, Oncol Drug Discovery Unit, Cambridge, MA USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-115086
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2946
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication
    Ishikawa, Y.
    Nakayama, K.
    Morimoto, M.
    Mizutani, A.
    Nakayama, A.
    Toyoshima, K.
    Hayashi, A.
    Takagi, S.
    Dairiki, R.
    Miyashita, H.
    Matsumoto, S.
    Gamo, K.
    Nomura, T.
    Nakamura, K.
    ONCOGENESIS, 2017, 6 : e377 - e377
  • [42] Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
    A Craig Lockhart
    Todd M. Bauer
    Charu Aggarwal
    Carrie B. Lee
    R Donald Harvey
    Roger B. Cohen
    Farhad Sedarati
    Tsz Keung Nip
    Hélène Faessel
    Ajeeta B. Dash
    Bruce J. Dezube
    Douglas V. Faller
    Afshin Dowlati
    Investigational New Drugs, 2019, 37 : 87 - 97
  • [43] Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
    Swords, Ronan T.
    Kelly, Kevin R.
    Smith, Peter G.
    Garnsey, James J.
    Mahalingam, Devalingam
    Medina, Ernest
    Oberheu, Kelli
    Padmanabhan, Swaminathan
    O'Dwyer, Michael
    Nawrocki, Steffan T.
    Giles, Francis J.
    Carew, Jennifer S.
    BLOOD, 2010, 115 (18) : 3796 - 3800
  • [44] Inhibition of the MEK/ERK Pathway Sensitizes Acute Lymphoblastic Leukemia Cells to the NEDD8-Activating Enzyme Inhibitor Pevonedistat Via Rebalancing BCL-2 Family Proteins
    Barredo, J. C.
    Zheng, S.
    Lelclerc, G. M.
    Leclerc, G. J.
    DeSalvo, J.
    Swords, R. T.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S101 - S101
  • [45] Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia
    J Khalife
    H S Radomska
    R Santhanam
    X Huang
    P Neviani
    J Saultz
    H Wang
    Y-Z Wu
    H Alachkar
    M Anghelina
    A Dorrance
    J Curfman
    C D Bloomfield
    B C Medeiros
    D Perrotti
    L J Lee
    R J Lee
    M A Caligiuri
    F Pichiorri
    C M Croce
    R Garzon
    M L Guzman
    J H Mendler
    G Marcucci
    Leukemia, 2015, 29 : 1981 - 1992
  • [46] A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
    Bhatia, Shailender
    Pavlick, Anna C.
    Boasberg, Peter
    Thompson, John A.
    Mulligan, George
    Pickard, Michael D.
    Faessel, Helene
    Dezube, Bruce J.
    Hamid, Omid
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (04) : 439 - 449
  • [47] Discovery of deoxyvasicinone derivatives as inhibitors of NEDD8-activating enzyme
    Zhong, Hai-Jing
    Leung, Ka-Ho
    Lin, Sheng
    Chan, Daniel Shiu-Hin
    Han, Quan-Bin
    Chan, Sharon Lai-Fung
    Ma, Dik-Lung
    Leung, Chung-Hang
    METHODS, 2015, 71 : 71 - 76
  • [48] Correction: Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication
    Y. Ishikawa
    K. Nakayama
    M. Morimoto
    A. Mizutani
    A. Nakayama
    K. Toyoshima
    A. Hayashi
    S. Takagi
    R. Dairiki
    H. Miyashita
    S. Matsumoto
    K. Gamo
    T. Nomura
    K. Nakamura
    Oncogenesis, 8
  • [49] MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with metastatic melanoma: Results of a phase I study.
    Bhatia, S.
    Hamid, O.
    Pavlick, A. C.
    Mulligan, G.
    Smith, P. G.
    Pickard, M. D.
    Shultz, M.
    Walker, R. M.
    Dezube, B.
    O'Day, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [50] A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
    Shailender Bhatia
    Anna C. Pavlick
    Peter Boasberg
    John A. Thompson
    George Mulligan
    Michael D. Pickard
    Hélène Faessel
    Bruce J. Dezube
    Omid Hamid
    Investigational New Drugs, 2016, 34 : 439 - 449
12345